At the close of SAGE THERAPEUTICS ($NASDAQ:SAGE)’ second quarter of FY2023, total revenue had risen 64.7% to USD 2.5 million compared to the prior year. Unfortunately, net income reported was -160.3 million, a rise from -126.3 million in the same period of the previous year.
GoodWhale conducted an analysis of SAGE THERAPEUTICS’s wellbeing and classified it as a ‘gorilla’. This type of company is generally characterized by having achieved stable and high revenue or earning growth due to its strong competitive advantage. Such companies are likely to draw the attention of investors looking for a promising return on their investments. The analysis revealed that SAGE THERAPEUTICS is in an intermediate health status with regard to its cashflows and debt, scoring 5/10. This shows that the company is likely to be able to pay off debt and fund future operations, although there may be some risks associated with doing so. In terms of other metrics, SAGE THERAPEUTICS fares well in asset inspections, profitability, and medium in growth but is weak in dividend. These metrics indicate a company with a solid portfolio of assets and potential for growth, but not necessarily offering a significant dividend return. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sage Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sage Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sage Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sage Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company has a strong focus on the development of novel therapies for the treatment of rare and orphan diseases. The company has a portfolio of products in various stages of development. The company’s products include Sage-547, an intravenous formulation of zolmitriptan for the treatment of migraines; Sage-217, an oral formulation of zolmitriptan for the treatment of cluster headaches; and Sage-689, an intranasal formulation of zolmitriptan for the treatment of migraines. The company is also developing product candidates for the treatment of Alzheimer’s disease, Parkinson’s disease, and epilepsy.
– Rocket Pharmaceuticals Inc ($NASDAQ:RCKT)
Rocket Pharmaceuticals Inc has a market cap of 1.48B as of 2022, a Return on Equity of -32.38%. The company focuses on the development and commercialization of innovative therapies for rare genetic diseases. The company’s mission is to provide hope to patients and their families by delivering life-changing treatments.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on the development of drugs for the treatment of cancer. Its lead product candidate is ALRN-6924, which is in Phase I clinical trials for the treatment of solid tumors and hematologic malignancies. Aileron Therapeutics Inc has a market cap of 305.62M as of 2022, a Return on Equity of -56.6%.
CinCor Pharma Inc is a pharmaceutical company with a market cap of 1.23B as of 2022 and a ROE of 78.34%. The company’s main focus is on the development and commercialization of treatments for cancer and other diseases. CinCor has a portfolio of products in various stages of development, including two products that are currently approved by the FDA. The company’s most advanced product is in Phase III clinical trials for the treatment of gastric cancer. CinCor is also developing a number of other products for the treatment of various cancers and other diseases.
SAGE THERAPEUTICS has seen a 64.7% year-over-year increase in total revenue to USD 2.5 million in its second quarter of FY2023. Unfortunately, the company reported a net income of USD -160.3 million, up from the prior year’s figure of -126.3 million. Despite the increase in revenue, investors have reacted negatively to this news, causing the company’s stock price to fall. As a result, investors should be cautious when considering SAGE THERAPEUTICS as an investment option.